APA (7th ed.) Citation

Cui, L., Golubczyk, D., Tolppanen, A., Boltze, J., Jolkkonen, J., Cui, L., & Tolppanen, A. (2019). Cell therapy for ischemic stroke: Are differences in preclinical and clinical study design responsible for the translational loss of efficacy? Annals of Neurology, 86(1), 5. https://doi.org/10.1002/ana.25493

Chicago Style (17th ed.) Citation

Cui, Li‐li, Dominika Golubczyk, Anna‐Maija Tolppanen, Johannes Boltze, Jukka Jolkkonen, Li-Li Cui, and Anna-Maija Tolppanen. "Cell Therapy for Ischemic Stroke: Are Differences in Preclinical and Clinical Study Design Responsible for the Translational Loss of Efficacy?" Annals of Neurology 86, no. 1 (2019): 5. https://doi.org/10.1002/ana.25493.

MLA (9th ed.) Citation

Cui, Li‐li, et al. "Cell Therapy for Ischemic Stroke: Are Differences in Preclinical and Clinical Study Design Responsible for the Translational Loss of Efficacy?" Annals of Neurology, vol. 86, no. 1, 2019, p. 5, https://doi.org/10.1002/ana.25493.